logo
Ottawa-based organization's pre-budget submission takes aim at women's health funding

Ottawa-based organization's pre-budget submission takes aim at women's health funding

Yahoo2 days ago
An Ottawa-based organization is urging the federal government to allocate millions of dollars in Budget 2025 to address gaps and misinformation in women's health, saying the money will advance women's health care across the country.
The Society of Obstetricians and Gynaecologists of Canada (SOGC) is a national organization dedicated to advancing women's health and advocating for better health-care policies across the country.
In its pre-budget submission, the organization outlined five key recommendations for government officials to consider while drafting Budget 2025, which is expected to drop in the fall.
One of those recommendations is a $20 million investment to close data gaps in women's health by creating a National Women's Health Data Dashboard and improve data collection strategies.
The SOGC says the dashboard, which should be a standardized and disaggregated database, will provide meaningful insights into key women's health indicators. This includes data on maternal mortality and morbidity, stillbirth and perinatal loss, menopause and endometriosis.
This will help patients make informed decisions about their health and also allow health-care providers to provide more responsive, equitable and cost-effective care, the SOGC added.
The organization also said the move will also have economic benefits because incomplete data leads to lost productivity and greater costs to the health-care system. Patients often have to foot hefty bills from unnecessary health-care costs.
Currently, provinces and territories are responsible for collecting this data and practices may vary widely.
'The federal government must take a leadership role in co-ordinating and standardizing this data collection, as approaches to health data collection across provinces and territories vary widely. Only national leadership can ensure consistency, comparability and the quality needed to build a reliable, actionable and nationally-focused database and dashboard,' the pre-budget submission read.
'Without co-ordinated, federally driven health data infrastructure, Canada will continue to miss emerging health trends, fall short in reducing system costs and fail to support women whose pain and illness limit their ability to fully participate in the economy.'
The recommendation comes after Prime Minister Mark Carney made several promises to protect women's rights in Canada throughout his federal election campaign earlier this year.
This includes investments to increase data collection to 'help address women's health gaps in Canada,' as well as investments into under-researched areas like postpartum maternal health.
But the platform did not provide specific details about how much money will be allocated to this initiative.
'Under a Liberal government, women's rights in Canada will never be compromised. We will protect these rights, and fight for true equity for women — in health, in the workplace, and in their access to fundamental rights,' the 2025 Liberal Party federal election platform reads.
The Liberal Party of Canada also pledged to invest into women's sexual and reproductive health care and health research, including those who identify as 2SLGBTQI+.
Women's health still under-researched, underfunded
Advocates have been talking about the lack of awareness and knowledge around women's health for years, saying it is a result of historical gender inequality in the research process.
Research published in April this year found that the percentage of research abstracts mentioning sex, gender and LGBTQ2S+ populations doubled or quadrupled from 2020 to 2023 but remained at under 10 per cent of overall funded research.
The number of female-specific research didn't change much between 2020 to 2023 — female-specific research only made up about seven per cent of all research between 2020 to 2023. A large bulk of that research focused on cancers (breast and gynecologic) or pregnancy.
This is despite the Health Portfolio Sex- and Gender-Based Analysis Plus Policy, which mandates for integrated sex and gender-based analyses in Canada. That policy came into effect in 2009 and aimed to promote diversity, equity and inclusion in health research.
'Mandates are not affecting the percentage of funding for women's health grants. More efforts and support beyond sex and gender mandates are needed to increase funding for and to diversify female-specific research beyond pregnancy and cancer. Research devoted to women's health factors is key to achieving personalized medicine and improved health outcomes for everyone,' the researchers wrote.
The lack of funded research into women's health also means many Canadians are misinformed and susceptible to disinformation.
A 2024 Abacus report commissioned by the Canadian Medical Association (CMA) showed that a majority of Canadians now seek news and information online over TV or radio. Female respondents were more likely than men to use social media and online platforms to find information on specific health conditions, symptoms or treatment options.
'Given the complexity of women's health issues, which can range from endometriosis, polycystic ovarian syndrome (PCOS), menopause and more, the quest for information is real. Women are more likely to experience dismissal or minimization of their symptoms, perpetuating stigma and shame,' the CMA said in a post published in March 2024.
'Algorithms that favour clicks and likes to the detriment of evidence-based facts make it increasingly difficult to discern health facts from fiction.'
A 2021 survey from three women's health foundations in Canada — the BC Women's Health Foundation, the Alberta Women's Health Foundation and the Women's College Hospital Foundation — found that a majority of Canadians were misinformed about women's health.
The survey suggests that 83 per cent of Canadians didn't know that 30 per cent of women suffer from periods severe enough to interfere with daily activities.
The report also said only 20 per cent of Canadians knew that heart disease kills more women than men each year.
'For so long, women's specific health needs have been largely ignored, under-researched, and underfunded. In fact, it takes 17 years for clinical research to filter down to medical practice, but women have only been included in trials for the past 20 years,' said Jennifer Bernard in 2021. Bernard is currently the president and CEO of the SickKids Foundation but was the former president and CEO of the Women's College Hospital Foundation from 2018 to 2023.
Our website is your destination for up-to-the-minute news, so make sure to bookmark our homepage and sign up for our newsletters so we can keep you informed.
Related
How to stay safe near the Ottawa River's Deschênes Rapids
Federal cuts are freezing new grads out of the public service
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs
BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs

Yahoo

time12 minutes ago

  • Yahoo

BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs

FRANKLIN LAKES, N.J., July 23, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announces the first pharma-sponsored combination product clinical trial using the BD Libertas™ Wearable Injector for subcutaneous delivery of complex biologics. The selection of BD Libertas™ Wearable Injector for this pharma-sponsored trial follows successful outcomes from more than 50 BD-conducted pre-clinical and clinical studies, including a device clinical study demonstrating excellent performance with 100% of study participants stating they would likely use the BD Libertas™ Wearable Injector if prescribedi,ii. The pharma-sponsored combination product clinical trial represents a significant advancement in accelerating innovation in drug-device combination products that provide greater flexibility for patients, including potential conversion from infused medications that require patients to travel to a hospital or clinic to more convenient patient care in various settings, including self-injection at home. "This trial demonstrates BD's commitment to helping pharma companies by advancing large-volume injection science, ensuring therapies are accessible and patient friendly by offering more efficient and convenient options for biologics," said Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems. "BD's enhanced testing capabilities acquired through ZebraSci and the proven capabilities of the BD Libertas™ Wearable Injector technology further position BD as an innovative leader in drug delivery." The BD Libertas™ Wearable Injector is an innovative, prefilled, patient ready-to-use drug delivery systemiii designed to enable delivery of complex biologics via subcutaneous injection. The biologics market is expected to grow to more than $670 billioniv by 2030 and for pharmaceutical companies developing these complex drugs, the BD Libertas™ Wearable Injector offers a customizable, patient-centric solution. The BD Libertas™ Wearable Injector: Supports delivery of high-viscosity biologics (up to 50 centipoise), enabling a wide range of subcutaneous therapies Is offered in 2 to 5 mL and 5 to 10 mL configurations providing flexibility for diverse therapeutic requirements Features a fully mechanical, patient ready-to-use design with a simple "peel, stick and click" mechanism, requiring no end-user filling or assemblyiii BD's ongoing validations of fill-finish and final assembly processes with multiple Contract Manufacturing Organizations (CMOs) enable the company to support pharmaceutical partners from development through commercial-scale production. For more information about how BD Libertas™ Wearable Injector is enabling biologic therapy delivery, visit About BD Libertas™ Wearable InjectorBD Libertas™ Wearable Injector is a product in development; some statements are forward looking and are subject to a variety of risks and uncertainties. BD Libertas™ Wearable Injector is a device component intended for drug-device combination products and not subject to FDA 510(k) clearance or separate EU CE mark certification. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit or connect with us on LinkedIn at X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. Contacts: Media: Investors: Fallon McLoughlin Adam Reiffe BD Corporate Communications BD Investor Relations 201.258.0361 201.847.6927 i Early feasibility clinical study of investigational BD Libertas™ Wearable Injector (WI) evaluated 5ml, non- Newtonian ~8cP subcutaneous placebo injections in 52 healthy adult subjects for functionality, tissue effects, subject tolerability (100mm Visual Analog Scale (VAS)) and acceptability (questionnaires with 5-point Likert or yes /no responses). Tissue effects were measured from WI removal post-injection through 24 hours with calipers (wheals) or graded on a 5-point scale (erythema, bleeding) from 0-none to 4-severe, significant, respectively. Where tissue effects were observed, the majority (>50%) were resolved within 60 minutes and all within 24 hours. Subject pain (100mm VAS) peaked mid-injection (mean 9.1mm, SD 13.4) and rapidly resolved within 30 minutes (mean 0 .4mm, SD 2.6). Subjects found acceptable (Likert agree + strongly agree or yes responses) their peak pain (≥90.2%), injection site appearance (≥92.2% ).ii Woodley, W. D. et al. Clinical Evaluation of an Investigational 5ml Wearable Injector in Healthy Human Subjects. Clin Transl Sci. 2021 May;14(3):859-869. Pharma filled and assemblediv Mordor Intelligence (2025). Biologics Market Size - Industry Report on Share, Growth Trends & Forecasts Analysis (2025 - 2030). View original content to download multimedia: SOURCE BD (Becton, Dickinson and Company) Sign in to access your portfolio

The president vows to slash medication cost to an unachievable degree.
The president vows to slash medication cost to an unachievable degree.

Yahoo

time12 minutes ago

  • Yahoo

The president vows to slash medication cost to an unachievable degree.

President Donald Trump has promised to reduce American drug prices by mathematically impossible figures of up to '1400 percent.' Speaking during a White House event attended by Republican members of Congress and his Cabinet, Trump said he would tackle the long-running issue of high medication costs in the U.S. But Trump did not set any achievable targets for that aim, instead outlining a range of percentages which would yield negative prices, meaning drug companies would have to pay people to take their medications.

Menopause: Why Women Shouldn't Suffer In Silence
Menopause: Why Women Shouldn't Suffer In Silence

Fox News

time14 minutes ago

  • Fox News

Menopause: Why Women Shouldn't Suffer In Silence

Martha puts menopause in the spotlight today. FOX News contributor and board-certified radiologist, Dr. Nicole Saphier, explains the false narrative surrounding treatments for menopause, including the risks of hormone replacement therapy, and why women have an outdated concept of proper treatments. Dr. Saphier takes a deeper dive into the commonly asked questions about breast cancer prevention and menopause, explaining why women shouldn't suffer in silence but rather advocate for their health and happiness throughout the aging process. Learn more about your ad choices. Visit

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store